

# CINV TRACKER

A TOOL TO HELP YOUR PATIENTS

Patients often don't self-report chemotherapy-induced nausea and vomiting (CINV), but it can have a significant impact on their treatment.<sup>1</sup> The screening questions below help identify patients who otherwise may have suffered in silence.

PATIENT NAME: \_\_\_\_\_

PHYSICIAN: \_\_\_\_\_

CHEMO REGIMEN: \_\_\_\_\_ DATE: \_\_\_\_\_ CYCLE: \_\_\_\_\_

ANTIEMETIC REGIMEN: \_\_\_\_\_

RN INITIALS: \_\_\_\_\_

DATE: \_\_\_\_\_

## How to use with your patient:

- Below are some questions that can be asked **prior** to the administration of the next chemotherapy cycle
- If your patient answers **YES** to any of the questions, it is considered breakthrough CINV\*
- American Society of Clinical Oncology guidelines recommend reevaluation and a change in CINV treatment before the next cycle if breakthrough CINV occurs<sup>2</sup>

Ask patients to think back to the days following their last chemotherapy treatment.

**Did you have any vomiting?**  Yes  No

If yes: Did it happen within 24 hours after chemotherapy?  Yes  No

Did it happen within 5 days of taking chemotherapy?  Yes  No

If yes, was it significant?  Yes  No

**Did you feel any nausea?**  Yes  No

If yes: Did it happen within 24 hours after chemotherapy?  Yes  No

Did it happen within 5 days of taking chemotherapy?  Yes  No

If yes, was it significant?  Yes  No

**Did you take any other medications that were prescribed to you to treat nausea and vomiting?**  Yes  No

**Did nausea and/or vomiting cause you to limit your everyday activities (eg, eating, working, caring for your loved ones)?**  Yes  No

**Did nausea and/or vomiting cause you to return for an office appointment or go to the ER (eg, hydration treatment)?**  Yes  No

\*Breakthrough CINV is nausea and/or vomiting that occurs at any time during days 1 to 5 postchemotherapy despite patients receiving a prophylactic antiemetic regimen prior to chemotherapy on day 1, and which may require the use of rescue medications.<sup>3</sup>

**References:** 1. Salsman et al. *J Natl Compr Canc Netw*. 2012. 2. Hesketh et al. *J Clin Oncol*. 2017. 3. Rao et al. *Am Health Drug Benefits*. 2012.